Keybank National Association OH lowered its position in shares of Alkermes PLC (NASDAQ:ALKS) by 51.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,700 shares of the company’s stock after selling 6,032 shares during the quarter. Keybank National Association OH’s holdings in Alkermes PLC were worth $330,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Daiwa SB Investments Ltd. acquired a new stake in shares of Alkermes PLC during the 2nd quarter worth about $166,000. Greenwood Capital Associates LLC increased its position in shares of Alkermes PLC by 2.4% during the 1st quarter. Greenwood Capital Associates LLC now owns 3,729 shares of the company’s stock worth $218,000 after purchasing an additional 89 shares in the last quarter. US Bancorp DE increased its position in shares of Alkermes PLC by 366.4% during the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after purchasing an additional 3,122 shares in the last quarter. Insight Capital Research & Management Inc. acquired a new stake in shares of Alkermes PLC during the 2nd quarter worth about $232,000. Finally, Aviance Capital Partners LLC acquired a new stake in shares of Alkermes PLC during the 2nd quarter worth about $232,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

In related news, Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total transaction of $82,365.00. Following the completion of the sale, the director now owns 9,500 shares of the company’s stock, valued at $521,645. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $51.29, for a total value of $695,800.14. Following the transaction, the chief accounting officer now directly owns 70,455 shares of the company’s stock, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. Insiders have sold 18,066 shares of company stock valued at $941,485 in the last ninety days. 5.34% of the stock is currently owned by company insiders.

WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/alkermes-plc-alks-position-lessened-by-keybank-national-association-oh/1560803.html.

A number of equities research analysts recently issued reports on ALKS shares. Credit Suisse Group set a $70.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, May 19th. ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Leerink Swann cut shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $68.00 to $61.00 in a research report on Tuesday, June 13th. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. Finally, BidaskClub cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $62.89.

Shares of Alkermes PLC (ALKS) opened at 52.29 on Thursday. The firm has a 50-day moving average of $52.09 and a 200 day moving average of $56.69. The firm’s market cap is $8.03 billion. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The business had revenue of $218.80 million during the quarter, compared to analysts’ expectations of $216.54 million. During the same quarter in the prior year, the business posted ($0.01) earnings per share. Alkermes PLC’s revenue was up 12.1% compared to the same quarter last year. On average, equities analysts predict that Alkermes PLC will post ($0.04) earnings per share for the current year.

Alkermes PLC Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.